<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000269421">
  <TermName>infliximab</TermName>
  <TermPronunciation>(in-FLIK-sih-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000710266" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;infliximab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000710265" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;infliximab&quot;" language="es" id="_4"/>
  <SpanishTermName>infliximab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Anticuerpo monoclonal que bloquea la acción de una citocina llamada factor alfa de necrosis tumoral. Está en estudio para tratar y prevenir la pérdida de peso y la pérdida de apetito de los pacientes con cáncer avanzado. Es un anticuerpo monoclonal.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2002-12-21</DateFirstPublished>
</GlossaryTerm>
